Antipsychotics, other psychotropics, and the risk of death in patients with dementia: Number needed to harm

JAMA Psychiatry

Volumn 72, Issue 5, 2015, Pages 438-445

  Maust, Donovan T ^a,b   Kim, Hyungjin Myra ^b,c   Seyfried, Lisa S ^a   Chiang, Claire ^a,b   Kavanagh, Janet ^a   Schneider, Lon S ^d   Kales, Helen C ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; VALPROIC ACID; DIBENZOTHIAZEPINE DERIVATIVE;

AGED; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CASE CONTROL STUDY; CHARLSON COMORBIDITY INDEX; COMORBIDITY; DELIRIUM; DEMENTIA; DEPRESSION; DOSE RESPONSE; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTTRAUMATIC STRESS DISORDER; RETROSPECTIVE STUDY; RISK ASSESSMENT; COMPARATIVE STUDY; EPIDEMIOLOGY; MIDDLE AGED; PSYCHOLOGY; REGISTER; RISK; STATISTICS AND NUMERICAL DATA; UNITED STATES; VETERAN;

AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CASE-CONTROL STUDIES; DEMENTIA; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PSYCHOTROPIC DRUGS; QUETIAPINE FUMARATE; REGISTRIES; RETROSPECTIVE STUDIES; RISK; RISPERIDONE; UNITED STATES; VETERANS;

EID: 84929321502     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.3018     Document Type: Article

References (32)

1. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191-210.
2. Sultzer DL, Davis SM, Tariot PN, et al CATIE-AD Study Group. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844-854.
3. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306(12):1359-1369.
4. Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med. 2012;367(16):1497-1507.
5. Schneider LS, Tariot PN, Dagerman KS, et al CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525-1538.
6. Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry. 2004;65(suppl 9):21-24.
7. US Food and Drug Administration. Risperdal (risperidone) dear healthcare professional letter Apr 2003. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm168933.htm. Published April 16, 2003. Accessed February 2, 2014.
8. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-1943.
9. US Food and Drug Administration. Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. US Department of Health and Human Services. http://www.fda.gov/Drugs/DrugSafety/ucm053171.htm. Accessed February 2, 2014.
10. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335-2341.
11. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-632.
12. US Food and Drug Administration. Information for healthcare professionals: information on conventional antipsychotics. US Department of Health and Human Services. http://www.fda.gov/Drugs/DrugSafety/ucm124830.htm. Accessed February 2, 2014
13. Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71-79.
14. Kales HC, Zivin K, Kim HM, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry. 2011;68(2):190-197.
15. Gerhard T, Huybrechts K, Olfson M, et al. Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry. 2014;205(1):44-51.
16. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012;344:e977.
17. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452-454.
18. Kales HC, Valenstein M, Kim HM, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007;164(10):1568-1576.
19. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596-608.
20. Porsteinsson AP, Drye LT, Pollock BG, et al; CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682-691.
21. Fillenbaum GG, Burchett BM, Blazer DG. Identifying a National Death Index match. Am J Epidemiol. 2009;170(4):515-518.
22. Kales HC, Kamholz BA, Visnic SG, Blow FC. Recorded delirium in a national sample of elderly inpatients: potential implications for recognition. J Geriatr Psychiatry Neurol. 2003;16(1):32-38.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
24. Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247-1256.
25. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho B-C. Antipsychotic dose equivalents and dose-years: a standardizedmethod for comparing exposure to different drugs. Biol Psychiatry. 2010;67(3):255-262.
26. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med. 1991;10(4):585-598.
27. Maglione M, Maher AR, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Rockville, MD: Agency for Healthcare Research & Quality; 2011.
28. Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc. 2011;59(3):473-481.
29. Lopez OL, Becker JT, Chang Y-F, et al. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry. 2013;170(9):1051-1058.
30. Tun S-M, Murman DL, Long HL, Colenda CC, von Eye A. Predictive validity of neuropsychiatric subgroups on nursing home placement and survival in patients with Alzheimer disease. Am J Geriatr Psychiatry. 2007;15(4):314-327.
31. Rabins PV, Lyketsos CG. Antipsychotic drugs in dementia: what should be made of the risks? JAMA. 2005;294(15):1963-1965.
32. Treloar A, Crugel M, Prasanna A, et al. Ethical dilemmas: should antipsychotics ever be prescribed for people with dementia? Br J Psychiatry. 2010;197(2):88-90.